Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting
Stock Information for Actinium Pharmaceuticals Inc. (Delaware)
Loading
Please wait while we load your information from QuoteMedia.